Dupilumab, an interleukin-4 (IL-4) receptor subunit blocking the function of T-helper 2 (Th2)-mediated cytokines is the first FDA biologic approved for the treatment of moderate-to-severe atopic dermatitis (AD). Several adverse effects have been associated with dupilumab with the emergence of case reports describing psoriasis and psoriasiform dermatitis as a potential side effect. Theories proposed in the pathogenesis of dupilumab induced psoriasis include a Th-1 overdrive based mechanism. Here, we report an additional case of psoriasiform dermatitis following dupilumab therapy in a young Middle Eastern male with a long-standing history of atopic nummular dermatitis.